 Biosimilar Pharmaceuticals
"Biosimilar Pharmaceuticals" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
BIOLOGIC PRODUCTS that are imitations but not exact replicas of innovator products.
| Descriptor ID |
D059451
|
| MeSH Number(s) |
D20.215.261
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Biosimilar Pharmaceuticals".
Below are MeSH descriptors whose meaning is more specific than "Biosimilar Pharmaceuticals".
This graph shows the total number of publications written about "Biosimilar Pharmaceuticals" by people in UAMS Profiles by year, and whether "Biosimilar Pharmaceuticals" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 1 | 0 | 1 | | 2022 | 3 | 0 | 3 | | 2014 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Biosimilar Pharmaceuticals" by people in Profiles over the past ten years.
-
McNicol M, Abdel-Rasoul M, McClinchie MG, Morris GA, Boyle B, Dotson JL, Michel HK, Maltz RM. Clinical outcomes and cost savings of a nonmedical switch to a biosimilar in children/young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2024 03; 78(3):644-652.
-
Ly S, Nedosekin D, Wong HK. Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin. Am J Clin Dermatol. 2023 Mar; 24(2):247-273.
-
Bachu RD, Abou-Dahech M, Balaji S, Boddu SHS, Amos S, Singh V, Babu RJ, Tiwari AK. Oncology biosimilars: New developments and future directions. Cancer Rep (Hoboken). 2022 11; 5(11):e1720.
-
Yossef L, Wright M, Benedict J, Morris GA, McNicol M, Boyle B, Dotson JL, Michel HK, Maltz RM. Patient and Caregivers' Perspectives on Biosimilar Use in Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2022 07 01; 75(1):59-63.
-
Morris GA, McNicol M, Boyle B, Donegan A, Dotson J, Michel HK, Maltz RM. Increasing Biosimilar Utilization at a Pediatric Inflammatory Bowel Disease Center and Associated Cost Savings: Show Me the Money. Inflamm Bowel Dis. 2022 03 30; 28(4):531-538.
-
Thompson AM, Atluri S, Price KN, Hsiao JL, Shi VY. Medicaid and Medicare Part B spending on immunomodulators and biosimilars. J Dermatolog Treat. 2022 May; 33(3):1762-1764.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|